Background {#Sec1}
==========

The use of echocardiography by intensivists is rapidly growing \[[@CR1]\]. Transthoracic echocardiography (TTE) is performed at the bedside, provides clinically relevant information and is safe in terms of radiation. TTE can be used to estimate dynamic parameters such as cardiac output (CO) but using TTE for these kinds of dynamic measurements is not without possible flaws \[[@CR2]\].

To detect changes in CO using TTE, successive measurements of CO are needed. To get accurate results, the CO measurements should ideally be taken at exactly the same location.

The Probefix is a non-invasive external ultrasound holder (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}) which is strapped on to the patient with the use of non-traumatic straps.Fig. 1Description of the Probefix Fig. 2Components of the Probefix Fig. 3Example of the fixation of the Probefix on a patient

When properly attached to the patient, the Probefix offers the opportunity to measure dynamic TTE parameters such as CO at exactly the same position thereby possibly increasing measurement accuracy.

To this date, there are no data on the use of the Probefix on adult intensive care patients. The Probefix has already been used in a study on adult outpatient cardiology patients \[[@CR3]\] and another tailored holder for echocardiography was described in a study on 5 pediatric patients \[[@CR4]\]. We designed a feasibility study to determine whether the Probefix can be used on adult intensive care patients for the purpose of measuring CO. CO with TTE with and without the Probefix was measured by using CO measurements made by the Flotrac as a reference. The Flotrac is a system that monitors CO by analyzing the systolic arterial pressure wave. The arterial catheter of the Flotrac system can be placed in the radial artery and has no need for pulmonary artery catheterization or other calibration \[[@CR6]\].

Because there is variation between CO measurements between TTE and Flotrac, it will be difficult to assess the use of the Probefix during random CO measurements. It is more interesting to know whether possible changes in CO measurements will be the same after a therapeutic intervention such as a bolus of fluid.

Besides CO, the Flotrac system monitors stroke volume and calculates the stroke volume variation (SVV). SVV is the percentage variation of stroke volume measured during a 20-s interval. Monitoring SVV can be helpful in detecting hypovolemia. When stroke volume variation is above 10%, hypovolemia is present \[[@CR7]\]. When hypovolemia is detected with the Flotrac, a passive leg raising test (PLR) can be performed. During PLR, 150--200 mL of blood returns from the lower extremity veins to the central circulation \[[@CR8]\]. With PLR, a reversible volume challenge is provided \[[@CR9]\]. This is in contrast to an infusion of fluid (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Apical 5 chamber view with pulsed wave Doppler sample volume

Methods {#Sec2}
=======

In this prospective pilot feasibility study, the Flotrac system was used to detect possible hypovolemia (SVV \> 10%) and Flotrac CO measurements were compared with the TTE CO measurements (with and without the use of the Probefix). CO was measured before and after a PLR test.

Primary endpoints {#Sec3}
-----------------

Percentage of patients in which the Probefix can be used.

The correlation between the measurements done by Flotrac and TTE with and without Probefix.

Although no side effects are to be expected, we monitored the patients after the Probefix was removed for any skin damage. Possible skin damage was graded into three categories:No skin marksMild skin marks (no treatment necessary)Severe skin marks (surgical or medical treatment necessary)

If awake, the patients were asked whether they felt the Probefix to be unpleasant on a scale of 0--10 (0 being: I did not feel anything and 10 being very unpleasant).

Inclusion criteria {#Sec4}
------------------

Adult intensive care patients (≥ 18 years), with hypovolemia detected with Flotrac (SVV \> 10%).

Exclusion criteria {#Sec5}
------------------

Pregnancy, atrial fibrillation or other irregular heart rhythm, pulmonary edema, PLR not possible (e.g., neurological disease, spinal trauma, restricted limb movement, deep venous thrombosis, or any other reason as indicated by the attending intensivist) or age \< 18 (years).

Measurements {#Sec6}
------------

After detection of SVV of more than 10% by Flotrac, patients were eligible for inclusion and consent was asked. The TTE studies were done by 2 investigators (MB and FB) with Philips Affinity using the Phased Array probe; the patients were in supine position.

First in the parasternal long axis view (PLAX), the left ventricle outflow tract (LVOT) was measured in cm. Then, the following protocol was executed:

Measurements with Probefix {#Sec7}
--------------------------

*Step 1*: The Probefix is attached to the patient.

*Step 2*: An apical 5 chamber view was obtained with a 2.5-MHz probe. A pulsed wave Doppler sample volume was measured just below the aortic valve (Fig. [2](#Fig2){ref-type="fig"}), sweep speed: 150 mm/s.

A velocity time integral (VTI) was calculated by tracing the envelope velocity. CO measurements were calculated by combining this result with the measurement of the opening of the aortic diameter, obtained in the PLAX.

*Step 3*: PLR test.

*Stage 1*: raise the lower limbs of the patient to a 45° while the patient's trunk is lowered in supine position.

*Stage 2*: after 1 min, measure the CO (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5The two positions in PLR

*Step 4*: Steps 2--4 are repeated without the use of the Probefix.

Measurements without Probefix {#Sec50}
-----------------------------

Repeat step 2 and 3.

Statistical analysis {#Sec8}
--------------------

Primary study parameter(s)Percentage of patients in which the Probefix can be used.Scatter plots are constructed and the limits of agreement are calculated.

Secondary study parameter(s) {#Sec9}
----------------------------

Possible side effects of the Probefix.

Descriptive statistics are presented as mean with standard deviation for normally distributed continuous data.

The local ethic committee approved the study (NL62664.091.17); informed consent was obtained from all participants (or their next of kin) included in the study.

Results {#Sec10}
=======

From May 2018 to April 2019, ten patients (six female and four male patients) were included.

In Table [1](#Tab1){ref-type="table"}, patient characteristics are described.Table 1Patient characteristicsAgeM/FBMIDiagnosisMode of ventilationProbefix feasible?Patient 170M23.1Out of hospital cardiac arrestPressure ControlYesPatient 264F24Out of hospital cardiac arrestPressure regulated volume controlYesPatient 369F23.4PneumoniaPressure supportYesPatient 467F23Chronic bronchitisPressure supportYesPatient 545F17.7PneumoniaPressure supportYesPatient 659M19.4Abdominal sepsisPressure supportYesPatient 768F24.2Interstitial lung diseasePressure supportYesPatient 861M24.5PneumoniaPressure supportNoPatient 973M22.8PneumoniaPressure controlYesPatient 1063F25.4Out of hospital cardiac arrestPressure supportNoMean [±]{.ul} SD63.9 [±]{.ul} 7.923.5 [±]{.ul} 3.1*M* male, *F* female, *BMI* body mass index, *SD* standard deviation

In eight patients (80%), the Probefix could be used properly leading to interpretable measurements. In two patients, insufficient views with the Probefix were obtained and in these patients, there were sufficient views using the TTE probe manually; so, the problem was Probefix related and not TTE related.

One patient was breathing spontaneously, three patients were on controlled mechanical ventilation and six patients received pressure support. Mean peak inspiratory pressure was 13 cm H~2~O (± 6.9), mean post expiratory end pressure 6 cm H~2~O (± 5.1), mean tidal volume was 480 mL (± 110) and mean LVOT was 2.1 cm (± 0.23).

When compared to the Flotrac measurements, there was no significant difference in correlation between TTE measurements with or without the use of the Probefix with the CO measurements done by Flotrac as a reference (Figs. [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}).Fig. 6Scatter plot transthoracic echo (TTE) cardiac output (CO) vs. Flotrac with (green points) and without the use of Probefix (blue points) Fig. 7Scatter plot transthoracic echo (TTE) cardiac output (CO) vs. Flotrac with (green points) and without the use of Probefix (blue points) after passive leg raising (PLR)

There were no serious skin lesions after the use of the Probefix. In four patients, there were minor skin marks that disappeared after some minutes. There was only one patient able to comment on the use of the Probefix and he reported only mild discomfort (2 on a scale of 10). In all patients, the time needed to process the protocol was within 15 min.

Discussion {#Sec11}
==========

We demonstrated in this small feasibility study that the Probefix could be used in eight of ten adult intensive care patients. All but one patient (patient 6) were medical patients. Male and female patients were included and patients were both on controlled and support mechanical ventilation. When compared to CO measurements using Flotrac, there was no statistical difference between CO measurements by TTE with or without the Probefix.

Our study is small and as far as we know the first on adult intensive care patient in which the use of Probefix is described. As mentioned before, there is already a small case study on pediatric intensive care patients but none on adult intensive care patients \[[@CR5].\]

The number of included patients was too small to be able to conclude whether the use of the Probefix will lead to more accurate CO measurements but the opposite was also not found.

We know that measuring CO on intensive care patients using TTE is difficult in terms of comparison to other techniques such as thermodilution techniques \[[@CR2]\] but it is feasible when done by intensivists \[[@CR10]\]. In this study, only one heartbeat to measure CO using TTE was used which is fewer then normally performed but the aim of this study was primarily to assess the feasibility of the Probefix, not to establish the accuracy of the TTE CO measurements. By adding a PLR test to this study, we investigated also whether the Probefix could be used for dynamic measurements and using the PLR test, the possible side effects of volume loading were diminished.

In this study, TTE measurements were compared to the measurements done by Flotrac. We acknowledge the fact that there are doubts about the usefulness of pulse pressure analysis as a monitoring tool on the intensive care \[[@CR11], [@CR12]\] but we think that the Flotrac measurements could be used as controls to compare the TTE measurements with and without the use of the Probefix.

No skin injuries in the studied patients were found. Whether Probefix creates pressure sores with longer attachment periods needs to be investigated. Nine of ten patients could not comment on the (dis)comfort of the Probefix due to sedative medication so on this one comment only we cannot speculate on this aspect of the use of Probefix.

There are many interesting options for the use of Probefix; eventually, its use enables continuous non-invasive CO measurements.

For this development, we need software that can translate the LVOT-VTI TTE images to real-time CO. By optimizing TTE for continuous CO monitoring, the use of more invasive techniques can be greatly diminished making this development of interest for almost every patient in the intensive care unit.

Conclusion {#Sec12}
==========

In this small feasibility study, it was shown that the Probefix can be used in eight out of ten adult intensive care patients for measuring CO also after a PLR test. More research is needed to further evaluate this new technique aiming at aspects such as accuracy, efficacy and costs.
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